NVCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Novocure Ltd (NVCR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has strong positive catalysts, including FDA approval for a new treatment, insider buying, and revenue growth. Despite short-term financial challenges, the long-term growth potential and improving sentiment make it a solid investment opportunity.
The MACD is positive and expanding, indicating a bullish trend. RSI is neutral at 65.132, and moving averages are converging, suggesting potential for upward momentum. Key resistance levels are at 14.547 and 15.673, with support at 12.725 and 10.903.
FDA approval for Optune Pax for pancreatic cancer, record net revenue of $655 million in 2025, insider buying increased by 330.05%, and strong analyst upgrades with increased price targets.
Declining net income and EPS in Q4 2025, along with a drop in gross margin. Concerns over potential ACA and Medicare changes as highlighted by analysts.
In Q4 2025, revenue increased by 8.11% YoY to $174.35 million, but net income dropped by -62.84% YoY to -$24.5 million. EPS also declined by -63.93% YoY to -$0.22, and gross margin fell by 4.33% YoY to 75.82%. Despite these declines, the company projects 2026 net revenues between $675 million and $705 million, indicating growth expectations.
H.C. Wainwright raised the price target to $47 from $39 with a Buy rating, citing FDA approval for Optune Pax. Evercore ISI lowered the price target to $20 from $22 but maintained an Outperform rating, noting positive trends in MedTech and recovering markets.
